REGN Long Put Strategy
REGN (Regeneron Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC.
REGN (Regeneron Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $74.16B, a trailing P/E of 16.93, a beta of 0.30 versus the broader market, a 52-week range of 476.49-821.11, average daily share volume of 681K, a public-listing history dating back to 1991, approximately 15K full-time employees. These structural characteristics shape how REGN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.30 indicates REGN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. REGN pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a long put on REGN?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current REGN snapshot
As of May 15, 2026, spot at $698.66, ATM IV 36.86%, IV rank 46.63%, expected move 10.57%. The long put on REGN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this long put structure on REGN specifically: REGN IV at 36.86% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 10.57% (roughly $73.84 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated REGN expiries trade a higher absolute premium for lower per-day decay. Position sizing on REGN should anchor to the underlying notional of $698.66 per share and to the trader's directional view on REGN stock.
REGN long put setup
The REGN long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With REGN near $698.66, the first option leg uses a $700.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed REGN chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 REGN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $700.00 | $28.85 |
REGN long put risk and reward
- Net Premium / Debit
- -$2,885.00
- Max Profit (per contract)
- $67,114.00
- Max Loss (per contract)
- -$2,885.00
- Breakeven(s)
- $671.15
- Risk / Reward Ratio
- 23.263
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
REGN long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on REGN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$67,114.00 |
| $154.49 | -77.9% | +$51,666.35 |
| $308.96 | -55.8% | +$36,218.70 |
| $463.44 | -33.7% | +$20,771.06 |
| $617.92 | -11.6% | +$5,323.41 |
| $772.39 | +10.6% | -$2,885.00 |
| $926.87 | +32.7% | -$2,885.00 |
| $1,081.35 | +54.8% | -$2,885.00 |
| $1,235.82 | +76.9% | -$2,885.00 |
| $1,390.30 | +99.0% | -$2,885.00 |
When traders use long put on REGN
Long puts on REGN hedge an existing long REGN stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying REGN exposure being hedged.
REGN thesis for this long put
The market-implied 1-standard-deviation range for REGN extends from approximately $624.82 on the downside to $772.50 on the upside. A REGN long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long REGN position with one put per 100 shares held. Current REGN IV rank near 46.63% is mid-range against its 1-year distribution, so the IV signal is neutral; the long put thesis on REGN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, REGN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to REGN-specific events.
REGN long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. REGN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move REGN alongside the broader basket even when REGN-specific fundamentals are unchanged. Long-premium structures like a long put on REGN are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current REGN chain quotes before placing a trade.
Frequently asked questions
- What is a long put on REGN?
- A long put on REGN is the long put strategy applied to REGN (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With REGN stock trading near $698.66, the strikes shown on this page are snapped to the nearest listed REGN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are REGN long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the REGN long put priced from the end-of-day chain at a 30-day expiry (ATM IV 36.86%), the computed maximum profit is $67,114.00 per contract and the computed maximum loss is -$2,885.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a REGN long put?
- The breakeven for the REGN long put priced on this page is roughly $671.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current REGN market-implied 1-standard-deviation expected move is approximately 10.57%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on REGN?
- Long puts on REGN hedge an existing long REGN stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying REGN exposure being hedged.
- How does current REGN implied volatility affect this long put?
- REGN ATM IV is at 36.86% with IV rank near 46.63%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.